SBC Medical Group Holdings Inc (SBC) Stock Analysis

Verdict: WATCH (do not buy)

Despite elite 36% operating margins and a deep value 7.5x P/E, aggressive CEO selling and negative earnings growth create a value trap risk.

Investment score: 58/100

Analysis as of

Is SBC Medical Group Holdings Inc stock worth reviewing? The TradeMates thesis

SBC is fundamentally robust with 24% net margins and a $163M cash pile, but it is technically broken due to heavy insider selling. The model sees a high-reward setup if support at $2.80 holds, but warns of the 'falling knife' risk.

7-factor investment score

SBC Medical Group Holdings Inc opportunities and risks

What speaks for SBC

What speaks against SBC

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
SBC7.5x1.8x2.7x70.2%24.1%14.3%
CCRNn/a0.4xn/a19.8%-9.8%9.1%
NRC44.6x3.0x17.6x55.9%6.5%4.2%
NRC44.6x3.0x17.6x55.9%6.5%4.2%
VMD26.6x1.4x7.5x57.3%5.2%6.6%
AIRSn/a2.3x94.6x60.6%-7.4%2.0%
Peer median26.6x2.3x17.6x55.9%5.2%4.2%

Frequently asked questions about SBC Medical Group Holdings Inc (SBC)

Is SBC stock a good investment?

The TradeMates model rates SBC Medical Group Holdings Inc as WATCH (do not buy) with an investment score of 58/100. SBC is fundamentally robust with 24% net margins and a $163M cash pile, but it is technically broken due to heavy insider selling. The model sees a high-reward setup if support at $2.80 holds, but warns of the 'falling knife' risk. This is algorithmic model output, not personal investment advice.

Is SBC stock a buy?

The TradeMates model verdict for SBC is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.